- ►annals.org [PDF] LA Linkins, PT Choi, JD Douketis - Annals of internal medicine, 2003 - Am Coll Physicians Background: Clinicians should consider the clinical impact of
anticoagulant-related bleeding when deciding on the duration of anticoagulant
therapy in patients with venous thromboembolism. Purpose: To provide ... Cited by 208 - Related articles - BL Direct - All 5 versions
D Sources, D Extraction, D Synthesis - Ann Intern Med, 2003 - hem-aids.ru Background: Clinicians should consider the clinical impact of
anticoagulant-related bleeding when deciding on the duration of anticoagulant
therapy in patients with venous thromboembolism. Purpose: To provide ... Related articles - View as HTML - All 3 versions
- ►pubget.com [PDF] G Agnelli, P Prandoni, C Becattini, M … - Annals of internal medicine, 2003 - Am Coll Physicians Background: The optimal duration of oral anticoagulant treat- ment after a first
episode of pulmonary embolism remains uncer- tain. Objective: To evaluate the
long-term clinical benefit of extend- ing a 3-month course of oral ... Cited by 116 - Related articles - BL Direct - All 10 versions
- ►ahajournals.org L Pinede, J Ninet, P Duhaut, S Chabaud, S … - Circulation, 2001 - Am Heart Assoc Methods and Results—We performed an open-label, randomized trial comparing a
short oral anticoagulant course (3 months for proximal deep vein thrombosis
[P-DVT] and/or pulmonary embolism [PE]; 6 weeks for isolated calf DVT ... Cited by 187 - Related articles - BL Direct - All 9 versions
- ►diegori.it [PDF] G Agnelli, P Prandoni, MG Santamaria, P … - New England Journal of Medicine, 2001 - content.nejm.org Results The primary intention-to-treat analysis showed that of 134 patients
assigned to continued oral anticoagulant therapy, 21 had a recurrence of venous
thromboembolism (15.7 percent; average follow-up, 37.8 months), as compared ... Cited by 300 - Related articles - BL Direct - All 10 versions
- ►velcec.com [PDF] C Kearon, JS Ginsberg, MJ Kovacs, DR … - New England Journal of Medicine, 2003 - content.nejm.org Clive Kearon, MB, Ph.D., Jeffrey S. Ginsberg, MD, Michael J. Kovacs, MD, David
R. Anderson, MD, Philip Wells, MD, Jim A. Julian, M.Math., Betsy MacKinnon,
M.Sc., Jeffrey I. Weitz, MD, Mark A. Crowther, MD, Sean Dolan, MD, ... Cited by 320 - Related articles - BL Direct - All 20 versions
JD Douketis, C Kearon, S Bates, EK Duku, JS … - Jama, 1998 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 372 - Related articles - BL Direct - All 3 versions
S Schulman, S Granqvist, M Holmstrom, A … - The New England journal of medicine, 1997 - nejm.highwire.org Results After four years of follow-up, there were 26 recurrences of venous
thromboembolism that fulfilled the diagnostic criteria, 23 in the group assigned
to six months of therapy (20.7 percent) and 3 in the group assigned to ... Cited by 381 - Related articles - BL Direct - All 7 versions
G Palareti, C Legnani, B Cosmi, G … - Thrombosis and haemostasis, 2002 - cat.inist.fr In some patients with previous venous thromboembolism(VTE) D-dimer
levels(D-Dimer) tend to increase after oral anticoagulant therapy(OAT) is
stopped. The aim of our study was to evaluate the predictive value of ... Cited by 202 - Related articles - BL Direct - All 3 versions
MN Levine, J Hirsh, M Gent, AG Turpie, J … - Thrombosis and haemostasis, 1995 - ncbi.nlm.nih.gov 1: Thromb Haemost. 1995 Aug;74(2):606-11. Optimal duration of oral
anticoagulant therapy: a randomized trial comparing four weeks ... Cited by 249 - Related articles - BL Direct - All 3 versions
